William M Burns, Head of Roche's Pharmaceuticals Division, said: "Roche is committed to exploring new research concepts that help to deliver the best possible care for people living with transplanted organs. Our decision to extend our financial support to the Foundation reflects Roche's continued commitment to the transplantation community and to innovation in scientific research. We are proud of our association with this pioneering Foundation."
Prof Phil Halloran, Chair of the Board of Trustees, said: "Innovation holds the key to improving the lives of people living with an organ transplant. It is always a challenge to secure funding for scientific research and Roche's support means that ROTRF is able to continue to fund and develop cutting-edge research worldwide. Ultimately, this helps advance our knowledge in transplantation and save lives."
ROTRF is a not-for-profit research foundation, whose remit to support ground-breaking research projects attracts new researchers with innovative scientific ideas, who aim to tackle areas of unmet medical need in organ transplantation. The first grants of this year have been awarded to nine scientists from around the world including Australia, Canada, Germany, UK and USA. Exceptionally, in 2003, almost half of the 89 applicants for research grants were from Europe.
New grants in 2003 focus on the need to further our understanding of the processes underlying chronic and acute rejection, to improve long-term graft survival. The objective of transplantation immunology is to specifically inhibit the body's response to the graft while leaving the re
Contact: Lisa Marriott